| The ecology of extended-spectrum β-lactamases (ESBLs) in the developed world Y Doi, A Iovleva, RA Bonomo Journal of travel medicine 24 (suppl_1), S44-S51, 2017 | 258 | 2017 |
| Carbapenem-resistant enterobacteriaceae A Iovleva, Y Doi Clinics in laboratory medicine 37 (2), 303-315, 2017 | 253 | 2017 |
| Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward ‘molecularly … NG El Chakhtoura, E Saade, A Iovleva, M Yasmin, B Wilson, F Perez, ... Expert review of anti-infective therapy 16 (2), 89-110, 2018 | 87 | 2018 |
| Genome dynamics of multidrug-resistant Acinetobacter baumannii during infection and treatment MS Wright, A Iovleva, MR Jacobs, RA Bonomo, MD Adams Genome medicine 8, 1-12, 2016 | 75 | 2016 |
| Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime RK Shields, A Iovleva, EG Kline, A Kawai, CL McElheny, Y Doi Clinical Infectious Diseases 71 (10), 2713-2716, 2020 | 61 | 2020 |
| Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in Enterobacter cloacae Due to AmpC R2 Loop Deletion A Kawai, CL McElheny, A Iovleva, EG Kline, N Sluis-Cremer, RK Shields, ... Antimicrobial agents and chemotherapy 64 (7), 10.1128/aac. 00198-20, 2020 | 59 | 2020 |
| In Vitro Evolution of Cefiderocol Resistance in an NDM-Producing Klebsiella pneumoniae Due to Functional Loss of CirA CL McElheny, EL Fowler, A Iovleva, RK Shields, Y Doi Microbiology spectrum 9 (3), e01779-21, 2021 | 32 | 2021 |
| Carbapenem-resistant Acinetobacter baumannii in US hospitals: diversification of circulating lineages and antimicrobial resistance A Iovleva, MM Mustapha, MP Griffith, L Komarow, C Luterbach, DR Evans, ... MBio 13 (2), e02759-21, 2022 | 27 | 2022 |
| Evolution and Transmission of Cefiderocol-Resistant Acinetobacter baumannii During an Outbreak in the Burn Intensive Care Unit SM Smoke, A Brophy, S Reveron, A Iovleva, EG Kline, M Marano, ... Clinical Infectious Diseases 76 (3), e1261-e1265, 2023 | 25 | 2023 |
| Genomic characterization of lytic bacteriophages targeting genetically diverse Pseudomonas aeruginosa clinical isolates HR Nordstrom, DR Evans, AG Finney, KJ Westbrook, PF Zamora, ... Iscience 25 (6), 2022 | 16 | 2022 |
| Rasamsonia sp: an emerging infection amongst chronic granulomatous disease patients. A case of disseminated infection by a putatively novel Rasamsonia argillacea species … A Babiker, N Gupta, CFC Gibas, NP Wiederhold, C Sanders, J Mele, ... Medical mycology case reports 24, 54-57, 2019 | 16 | 2019 |
| Characterization of KPC-82, a KPC-2 variant conferring resistance to ceftazidime-avibactam in a carbapenem-nonsusceptible clinical isolate of Citrobacter koseri F Lebreton, BW Corey, CL McElheny, A Iovleva, L Preston, KR Margulieux, ... Antimicrobial agents and chemotherapy 65 (7), 10.1128/aac. 00150-21, 2021 | 14 | 2021 |
| KPC-3–producing serratia marcescens outbreak between acute and long-term care facilities, Florida, USA A Jimenez, LM Abbo, O Martinez, B Shukla, K Sposato, A Iovleva, ... Emerging infectious diseases 26 (11), 2746, 2020 | 9 | 2020 |
| High-level carbapenem resistance in OXA-232-producing Raoultella ornithinolytica triggered by ertapenem therapy A Iovleva, RT Mettus, CL McElheny, MP Griffith, MM Mustapha, ... Antimicrobial agents and chemotherapy 64 (1), 10.1128/aac. 01335-19, 2019 | 9 | 2019 |
| Clinical Outcomes and Bacterial Characteristics of Carbapenem-resistant Acinetobacter baumannii Among Patients From Different Global Regions M Wang, L Ge, L Chen, L Komarow, B Hanson, J Reyes, E Cober, ... Clinical Infectious Diseases 78 (2), 248-258, 2024 | 8 | 2024 |
| Early initiation of three-drug combinations for the treatment of carbapenem-resistant A. baumannii among COVID-19 patients EL Heil, KC Claeys, EG Kline, TM Rogers, KM Squires, A Iovleva, Y Doi, ... Journal of Antimicrobial Chemotherapy 78 (4), 1034-1040, 2023 | 6 | 2023 |
| Reduced ceftazidime and ertapenem susceptibility due to production of OXA-2 in Klebsiella pneumoniae ST258 A Iovleva, RT Mettus, CL McElheny, MM Mustapha, D Van Tyne, ... Journal of Antimicrobial Chemotherapy 74 (8), 2203-2208, 2019 | 6 | 2019 |
| Isolation and Characterization of Lytic Bacteriophages Targeting Diverse Enterobacter spp. Clinical Isolates AG Finney, JM Perry, DR Evans, KJ Westbrook, CL McElheny, A Iovleva, ... Therapy, Applications, and Research 3 (1), 50-58, 2022 | 5 | 2022 |
| IS26-mediated plasmid reshuffling results in convergence of toxin–antitoxin systems but loss of resistance genes in XDR Klebsiella pneumoniae from a chronic … TL Luo, BW Corey, E Snesrud, A Iovleva, CL McElheny, LN Preston, ... Microbial genomics 8 (9), 000892, 2022 | 4 | 2022 |
| Ceftazidime/Avibactam and Ceftolozane/Tazobactam in Treatment of Pulmonary Infections by Imipenem Resistant Pseudomonas aeruginosa A Iovleva, F Perez, SH Marshall, AM Hujer, MR Jacobs, U Stiefel, A Ray, ... Open Forum Infectious Diseases 3 (suppl_1), 2003, 2016 | 4 | 2016 |
